The HemOnc Pulse Live at ASH: Thomas Martin, MD, on Frontline Treatment Advances, Novel Agents in Myeloma
By Chadi Nabhan, MD, MBA, FACP, Thomas Martin, MD - Last Updated: December 14, 2022The HemOnc Pulse, brought to you by Blood Cancers Today and the Society of Hematologic Oncology, checks in with Blood Cancers Today Editorial Board Member Thomas Martin, MD, during the 64th Annual American Society of Hematology Meeting and Exhibition. Dr. Martin discussed topics including advances in frontline treatments for multiple myeloma, the use of CD38-directed antibodies in patients with relapsed disease, combination therapies with bispecific T-cell engagers, the need for novel agents, and more, with host Chadi Nabhan, MD, MBA, FACP.
Post Tags:Myeloma ASH 22
Advertisement
Related Posts
Dr. Hill and colleagues presented their research on the CAR-T manufacturing approach during the 2023 ASCO meeting.
Health care disparities have been an "ongoing issue" for patients with cancer, especially in multiple myeloma.
AML Awareness Month is marked each June.
The study is currently enrolling patients who have previously received a Bruton tyrosine kinase inhibitor.
Dr. Dickinson discusses what he sees as the key highlights in lymphoma research during the summer 2023 conference season.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
670 Madison Ave.
Manalapan, NJ 07726